Clinical Trial Update: Study in Asia of the Combination of TACE With Sorafenib in HCC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in Asia evaluating the combination of transarterial chemoembolization (TACE) with sorafenib for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN